Total Payments
$21,592
2024 Payments
$3,122
Companies
86
Transactions
1,112
Medicare Patients
2,953
Medicare Billing
$705,480
Payment Breakdown by Category
Food & Beverage$19,032 (88.1%)
Education$2,480 (11.5%)
Gifts$79.49 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,032 | 1,070 | 88.1% |
| Education | $2,480 | 41 | 11.5% |
| Gift | $79.49 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,714 | 80 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,425 | 96 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,420 | 94 | $0 (2024) |
| Janssen Biotech, Inc. | $1,359 | 60 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,203 | 70 | $0 (2024) |
| PFIZER INC. | $1,106 | 81 | $0 (2024) |
| Merck Sharp & Dohme LLC | $949.93 | 64 | $0 (2024) |
| Genentech USA, Inc. | $925.95 | 69 | $0 (2023) |
| Gilead Sciences, Inc. | $743.79 | 27 | $0 (2024) |
| Astellas Pharma US Inc | $567.24 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,122 | 143 | Novartis Pharmaceuticals Corporation ($249.56) |
| 2023 | $2,830 | 117 | Astellas Pharma US Inc ($210.55) |
| 2022 | $1,677 | 79 | Gilead Sciences, Inc. ($244.57) |
| 2021 | $650.66 | 14 | Amgen Inc. ($182.49) |
| 2020 | $1,350 | 72 | Amgen Inc. ($230.20) |
| 2019 | $3,594 | 209 | Amgen Inc. ($485.45) |
| 2018 | $4,018 | 230 | Janssen Biotech, Inc. ($409.62) |
| 2017 | $4,351 | 248 | E.R. Squibb & Sons, L.L.C. ($467.21) |
All Payment Transactions
1,112 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.34 | General |
| 12/13/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $8.51 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $5.98 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $33.93 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $5.13 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.52 | General |
| Category: Hematology/Oncology | ||||||
| 12/03/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.98 | General |
| Category: Rare Disease | ||||||
| 11/21/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Oncology | ||||||
| 11/13/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $24.86 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: Oncology | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.93 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 816 | 1,868 | $951,179 | $194,949 |
| 2022 | 4 | 775 | 1,940 | $929,693 | $185,115 |
| 2021 | 4 | 709 | 1,856 | $780,075 | $182,733 |
| 2020 | 4 | 653 | 1,662 | $671,848 | $142,683 |
Total Patients
2,953
Total Services
7,326
Medicare Billing
$705,480
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 243 | 759 | $289,509 | $84,339 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 376 | 909 | $487,715 | $77,443 | 15.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 120 | 123 | $91,740 | $19,595 | 21.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 59 | 59 | $62,848 | $9,805 | 15.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $19,368 | $3,766 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 370 | 1,079 | $542,831 | $90,590 | 16.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 250 | 705 | $254,505 | $66,987 | 26.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 81 | 82 | $57,892 | $14,951 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 74 | 74 | $74,465 | $12,587 | 16.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 340 | 1,052 | $436,580 | $92,851 | 21.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 230 | 663 | $239,343 | $64,278 | 26.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 90 | 92 | $64,952 | $17,337 | 26.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 49 | 49 | $39,200 | $8,267 | 21.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 212 | 656 | $236,816 | $63,911 | 27.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 335 | 900 | $357,540 | $60,147 | 16.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 64 | 64 | $45,184 | $12,150 | 26.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 42 | 42 | $32,308 | $6,475 | 20.0% |
About Dr. Robert March, MD
Dr. Robert March, MD is a Hematology & Oncology healthcare provider based in Nyack, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1801005012.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert March, MD has received a total of $21,592 in payments from pharmaceutical and medical device companies, with $3,122 received in 2024. These payments were reported across 1,112 transactions from 86 companies. The most common payment nature is "Food and Beverage" ($19,032).
As a Medicare-enrolled provider, March has provided services to 2,953 Medicare beneficiaries, totaling 7,326 services with total Medicare billing of $705,480. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Nyack, NY
- Active Since 05/22/2007
- Last Updated 06/22/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801005012
Products in Payments
- OPDIVO (Biological) $984.70
- IMBRUVICA (Drug) $838.55
- KEYTRUDA (Biological) $820.16
- SIR-Spheres Microspheres (Device) $461.03
- KISQALI (Drug) $447.79
- Trodelvy (Drug) $437.09
- ELIQUIS (Drug) $400.36
- Lenvima (Drug) $360.68
- JAKAFI (Drug) $337.14
- Neulasta (Biological) $309.75
- VERZENIO (Drug) $309.53
- LYNPARZA (Drug) $298.11
- DARZALEX (Biological) $288.17
- IMFINZI (Drug) $272.22
- Nplate (Biological) $268.33
- Imbruvica (Drug) $265.67
- IBRANCE (Drug) $259.37
- ADCETRIS (Biological) $251.16
- FASLODEX (Drug) $241.53
- EPKINLY (Drug) $237.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nyack
Irina Rybalova, Md, MD
Hematology & Oncology — Payments: $18,316
Hematology & Oncology $18,316
Sung Ho Lee, M.d, M.D
Hematology & Oncology — Payments: $13,447
Hematology & Oncology $13,447
Dr. Aleksandra Mamorska-Dyga, M.d, M.D
Hematology & Oncology — Payments: $4,449
Hematology & Oncology $4,449
Dr. Michael Rader, M.d, M.D
Hematology & Oncology — Payments: $33.27
Hematology & Oncology $33.27